Medicare Coverage Decision for TMVR

CMS issued a National Coverage Decision under which transcatheter mitral valve repair (TMVR) will be reimbursed under Medicare with evidence development and subject to being performed by an interventional cardiologist and/or a cardiothoracic surgeon.

CMS/FDA Approve Colon Cancer Screening Test

After the Food and Drug Administration (FDA) Molecular and Clinical Genetics Panel’s favorable vote, in a joint coverage decision the FDA and CMS approved a stool-based DNA screening test used to detect abnormalities that may indicate colon cancer (the Cologuard test is manufactured by Exact Sciences Corp. of Madison, Wisconsin). To be covered under Medicare Part B, the individuals must be between 50-85 years old, be asymptomatic and at average risk of developing colorectal cancer.

December 31, 1969: | Page 1 Page 2 Page 3 Page 4



 -  2019

 +  2018